Dr. John A. Vanchiere, MD/PHD
Pediatric Infectious Disease (Pediatric Infectious Diseases Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 2003, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Infectious Diseases Physician primary
LA license MD023912 · TX license L6693 (first issued 2003; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Adm sarscv2 bvl 30mcg/.3ml a | 163 | 163 |
| Adm sarscv2 bvl 50mcg/.5ml a | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $102,834 in research payments for these studies, mostly to the institutions running them.
- A phase 2 randomized partially doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine administered in healthy toddlers 12 through 15 months of age
Pfizer Inc. - A master phase 123 protocol to investigate the safety tolerability and immunogenicity of bivalent BNT162B2 rna based vaccine candidates in healthy children
Pfizer Inc. - A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Tetraphase Pharmaceuticals, Inc. · Recruiting · NCT06794541 - A phase 2 randomized doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Pfizer Inc. - A phase 23 interventional safety pharmacokinetics and efficacy openlabel multicenter singlearm study to investigate orally administered PF07321332 nirmatrelvirritonavir in nonhospitalized symptomatic pediatric partici…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.